METiS Technologies, a global leader in AI-driven nanodelivery innovation, announced the successful completion of its RMB 400 million Series D financing round on August 5, 2025. The announcement was made at the Zhongguancun (Daxing) Cell and Gene Therapy Industrial Park, positioning the company as a key player in Beijing's expanding life sciences ecosystem.
Strategic Investment from Government-Backed Funds
The Series D round was co-led by the Beijing Medical and Health Industry Investment Fund and the Daxing Industrial Investment Fund. The Beijing Medical and Health Industry Investment Fund, one of eight major industrial funds established with Beijing Municipal Government support, focuses on innovative pharmaceuticals, advanced medical devices, and emerging technologies including cell and gene therapy (CGT) and digital health.
"Healthcare is a cornerstone of Beijing's innovation-driven strategy and a vital engine of emerging productivity," said Mr. REN Peng, Chairman and General Manager of Shunxi Management Co., Ltd. "With the launch of the city's AI+Healthcare Innovation Action Plan, Beijing is strategically integrating AI with life sciences to lead the next phase of high-quality growth. Our RMB 20 billion fund reflects our commitment to advancing innovation in CGT."
The new capital will accelerate METiS' core strategic initiatives, including automation upgrades to its proprietary platform, in-house pipeline development, expansion of global partnerships, and recruitment of world-class talent.
OpenCGT Platform Launch
As part of Beijing's broader CGT development strategy, METiS launched the OpenCGT platform designed to address key challenges in precision nanodelivery, reduce costs and complexity, and enable clinical translation of next-generation CGT therapies. The platform represents a cornerstone of Beijing's Three-Year Action Plan, launched in 2024 by five municipal authorities including the Municipal Science and Technology Commission and Zhongguancun Administrative Committee.
The plan aims to foster over 20 cutting-edge CGT companies by 2027 and establish a globally recognized CGT innovation cluster. CGT represents the third major wave of pharmaceutical innovation, following small molecules and biologics.
First Collaboration with AccurEdit Therapeutics
The OpenCGT platform's inaugural project enables AccurEdit Therapeutics to develop a liver-targeted CRISPR gene-editing therapy using mRNA-LNP delivery. AccurEdit Therapeutics, a pioneering biotech company developing precise, safe, and effective in vivo gene editing therapies for hereditary and acquired diseases, achieved a significant milestone in October 2023 by becoming the first and only company in China to demonstrate systemic CRISPR gene editing in humans with confirmed safety and efficacy.
The company has built a best-in-class, end-to-end platform for in vivo gene editing that integrates RNA synthesis, editing, and delivery technologies.
Proprietary AI Technology Platforms
METiS Technologies has developed three proprietary platform technologies that simulate, predict, and interpret nanoscale interactions. The AiLNP platform focuses on AI-driven nucleic acid delivery system design, while AiRNA provides AI-powered mRNA sequence optimization. The AiTEM platform specializes in AI-enabled small molecule formulation design.
These platforms enable rational design, optimization, and validation of next-generation nanomaterials and their payloads, targeting therapeutic applications across cancer, metabolic and autoimmune disorders, and neurodegenerative conditions.
Company Background and Leadership
Founded by a team of MIT-trained scientists with expertise in AI, quantum mechanics, nanomaterials, and advanced drug delivery, METiS Technologies operates at the intersection of artificial intelligence and nanomaterial science. Dr. Chris LAI, Co-founder and CEO, emphasized the company's commitment to the broader life sciences ecosystem.
"Solving the grand challenge of nanodelivery through AI innovation is not just METiS' mission—it's our commitment to the broader life sciences ecosystem," Dr. LAI stated. "We will continue to develop homegrown, world-class delivery technologies to support the high-quality growth of China's CGT industry."
The financing round also included continued support from CICC Capital, with Deputy General Manager HUANG Hantao noting the company's tremendous progress over the past two years and commitment to supporting future R&D collaborations, clinical development, talent acquisition, and capital market activities.
